UK′s Medicines and Healthcare products Regulatory Agency has approved sotrovimab for the treatment of COVID-19. The drug has been developed by GlaxoSmithKline and Vir Biotechnology.

The treatment has been approved after it was found to be safe and effective at reducing the risk of hospitalization and death in people with mild to moderate COVID-19, having an increased risk of progressing to severe disease. The drug decreased the risk of hospitalization and death by 79% in high-risk individuals with symptomatic COVID-19.

GSK has stated that a pre-clinical analysis of the antibody-based treatment suggests that the drug can work against the Omicron variant. The company said that more tests will be conducted on the drug to confirm the results… (ET Healthworld, December 2, 2021)